137 related articles for article (PubMed ID: 36114573)
1. Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center.
Zhu Y; Zhang X; Wei J; Yang C; Tong H; Mai W; Yang M; Qian J; Mao L; Meng H; Jin J; Yu W
Exp Hematol Oncol; 2022 Sep; 11(1):57. PubMed ID: 36114573
[TBL] [Abstract][Full Text] [Related]
2. Zanubrutinib-lenalidomide-rituximab (ZR
Wang Y; Xu J; Li P; Xu Y; Xue H; Liu P
Ann Hematol; 2024 Feb; 103(2):499-510. PubMed ID: 37957370
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.
Xu PP; Shi ZY; Qian Y; Cheng S; Zhu Y; Jiang L; Li JF; Fang H; Huang HY; Yi HM; Ouyang BS; Wang L; Zhao WL
Lancet Healthy Longev; 2022 Jul; 3(7):e481-e490. PubMed ID: 36102758
[TBL] [Abstract][Full Text] [Related]
4. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
Westin J; Davis RE; Feng L; Hagemeister F; Steiner R; Lee HJ; Fayad L; Nastoupil L; Ahmed S; Rodriguez A; Fanale M; Samaniego F; Iyer SP; Nair R; Oki Y; Fowler N; Wang M; Ma MCJ; Vega F; McDonnell T; Pinnix C; Griffith D; Lu Y; Tewari S; Sun R; Scott DW; Flowers CR; Neelapu S; Green MR
J Clin Oncol; 2023 Feb; 41(4):745-755. PubMed ID: 35952327
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
[TBL] [Abstract][Full Text] [Related]
6. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
7. [Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
Qin Y; Zhao FY; Zhou Y; Jiang SY; Yang S; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1034-1039. PubMed ID: 33342160
[No Abstract] [Full Text] [Related]
8. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Tian C; Chen Z; Li Y
J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
10. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
Paillassa J; Safa F; Troussard X
Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.
Li Y; Li Y; Zeng R; He Y; Liang L; Ou L; Su C; Zhou H; Xiao L
J Cancer; 2023; 14(17):3182-3190. PubMed ID: 37928429
[No Abstract] [Full Text] [Related]
13. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
[TBL] [Abstract][Full Text] [Related]
15. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.
Wu JQ; Song YP; Su LP; Zhang MZ; Li W; Hu Y; Zhang XH; Gao YH; Niu ZX; Feng R; Wang W; Peng JW; Li XL; Ouyang XN; Wu CP; Zhang WJ; Zeng Y; Xiao Z; Liang YM; Zhuang YZ; Wang JS; Sun ZM; Bai H; Cui TJ; Feng JF
Chin Med J (Engl); 2018 Aug; 131(15):1767-1775. PubMed ID: 30058572
[TBL] [Abstract][Full Text] [Related]
16. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Wang M; Fowler N; Wagner-Bartak N; Feng L; Romaguera J; Neelapu SS; Hagemeister F; Fanale M; Oki Y; Pro B; Shah J; Thomas S; Younes A; Hosing C; Zhang L; Newberry KJ; Desai M; Cheng N; Badillo M; Bejarano M; Chen Y; Young KH; Champlin R; Kwak L; Fayad L
Leukemia; 2013 Sep; 27(9):1902-9. PubMed ID: 23545991
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysis.
Wei R; Wu Y; Jiang S; Zhang A; Zhang L; Liu L; Wang Y; Zhang M; Mei H; Liu F; Xia L; Cui G; Fang J
Clin Exp Med; 2023 Dec; 23(8):4609-4621. PubMed ID: 37925380
[TBL] [Abstract][Full Text] [Related]
18. Reduced-Intensity Anthracycline-Free Chemoimmunotherapy in Elderly Patients With Newly Diagnosed or Relapsed Diffuse Large B-Cell Lymphoma.
Yohannan B; Rios A
J Hematol; 2023 Aug; 12(4):176-186. PubMed ID: 37692866
[TBL] [Abstract][Full Text] [Related]
19. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
Zinzani PL; Pellegrini C; Gandolfi L; Stefoni V; Quirini F; Derenzini E; Broccoli A; Argnani L; Pileri S; Baccarani M
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):462-6. PubMed ID: 21859554
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.
Bai JF; Han HX; Feng R; Li JT; Wang T; Zhang CL; Liu H
Oncologist; 2020 Aug; 25(8):e1202-e1208. PubMed ID: 32436258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]